Asklepion Pharmaceuticals: Private, focused on the development of IV Citrulline for rare pediatric diseases. First indication, the prevention of significant sequelae of pediatric acute cardiopulmonary bypass-induced lung injury, Ph 3 trial is ongoing. After receiving FDA and EMA registration, the company sold Cholbam, for bile acid synthesis defects and peroxisomal disorders, to Retrophin (RTRX) in 2015, providing an ongoing, quarterly revenue stream.
729 E. Pratt St
Suite 360
Baltimore, MD 21202
United States

Send Message to Request Information

Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.